ATE113834T1 - Zusammensetzung zur behandlung der schizophrenie. - Google Patents

Zusammensetzung zur behandlung der schizophrenie.

Info

Publication number
ATE113834T1
ATE113834T1 AT89909607T AT89909607T ATE113834T1 AT E113834 T1 ATE113834 T1 AT E113834T1 AT 89909607 T AT89909607 T AT 89909607T AT 89909607 T AT89909607 T AT 89909607T AT E113834 T1 ATE113834 T1 AT E113834T1
Authority
AT
Austria
Prior art keywords
pct
schizophrenia
treatment
sec
date
Prior art date
Application number
AT89909607T
Other languages
English (en)
Inventor
Andras Perenyi
Goswami Utpal
Mihaly Arato
Ede Frecska
Jozsef Knoll
Arpad Bela
Original Assignee
Chinoin Gyogyszer Es Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyogyszer Es Vegyeszet filed Critical Chinoin Gyogyszer Es Vegyeszet
Application granted granted Critical
Publication of ATE113834T1 publication Critical patent/ATE113834T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
AT89909607T 1988-08-17 1989-08-17 Zusammensetzung zur behandlung der schizophrenie. ATE113834T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU884374A HU208484B (en) 1988-08-17 1988-08-17 Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia

Publications (1)

Publication Number Publication Date
ATE113834T1 true ATE113834T1 (de) 1994-11-15

Family

ID=10967788

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89909607T ATE113834T1 (de) 1988-08-17 1989-08-17 Zusammensetzung zur behandlung der schizophrenie.

Country Status (9)

Country Link
US (1) US5151419A (de)
EP (1) EP0413771B1 (de)
JP (1) JPH0818977B2 (de)
AT (1) ATE113834T1 (de)
BG (1) BG60423B2 (de)
CA (1) CA1329129C (de)
DE (1) DE68919358T2 (de)
HU (1) HU208484B (de)
WO (1) WO1990001928A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
CA2107552C (en) * 1991-04-04 2001-08-28 William G. Tatton Use of deprenyl to maintain, prevent loss, or recover nerve cell function
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
HUT63579A (en) * 1991-12-20 1993-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing double-phase pharmaceutical compositions suitable for treating diseases occurring during neurodegenerative processes
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
SE9301112D0 (sv) * 1993-04-02 1993-04-02 Orion-Yhtymae Oy A new composition
FR2704756B1 (fr) * 1993-05-04 1995-07-28 Sanofi Elf Utilisation de la sélégiline en médecine vétérinaire.
DK0623344T3 (da) * 1993-05-04 2000-12-18 Ceva Sante Animale Anvendelse af selegilin i veterinær medicin
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
HU223475B1 (hu) * 1994-10-24 2004-07-28 Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. Selegilint tartalmazó liposzoma-készítmény és eljárás ennek előállítására
WO1996018386A1 (en) * 1994-12-14 1996-06-20 Enbalt Trading Limited Pharmaceutical tablet formulations for direct compression
CA2212412A1 (en) 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
BR9607057A (pt) * 1995-03-02 1998-06-09 Scherer Ltd R P Composições farmacêuticas compreendendo inibidores monoamina oxidase b
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
IL122484A0 (en) 1995-06-07 1998-06-15 Noven Pharma Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DK0866691T4 (da) * 1995-11-06 2005-06-06 Somerset Pharmaceuticals Inc Medikamenter til sublingual og bukkal administration af selegilin
EP0983062A4 (de) 1997-05-21 2002-10-23 Sloan Kettering Inst Cancer Verfahren zur erhöhung der konzentration von ascobinsäure im hirngewebe von personen
US6262111B1 (en) 1997-05-21 2001-07-17 Sloan-Kettering Institute For Cancer Research Method for increasing the concentration of ascorbic acid in brain tissues of a subject
US8058442B2 (en) * 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
WO2005051371A1 (en) * 2003-11-25 2005-06-09 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
US20070082953A1 (en) * 2003-12-18 2007-04-12 Rudolf-Giesbert Alken Use of l-dopa, derivatives thereof and medicaments comprising said compounds for the prophylaxis of psychotic diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN105168219B (zh) 2008-05-27 2018-11-20 细胞内治疗公司 用于睡眠障碍和其他疾病的方法和组合物
JP6045347B2 (ja) 2010-02-03 2016-12-14 ファーマ ツー ビー リミテッド ラサギリンの持続放出性製剤およびその使用
HUE053159T2 (hu) 2013-03-15 2021-06-28 Intra Cellular Therapies Inc Szerves vegyületek
IL305990B2 (en) 2013-12-03 2025-12-01 Intra Cellular Therapies Inc Long-acting injectable composition comprising polymeric microspheres of heterocycle fused gamma-carboline compounds or a pharmaceutical composition for sustained or delayed release comprising the compounds and their use in the treatment of bipolar disorder i and/or bipolar ii disorder
MX365969B (es) 2014-04-04 2019-06-21 Intra Cellular Therapies Inc Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio.
CN108883111B (zh) 2016-01-26 2021-10-08 细胞内治疗公司 有机化合物
PL3407889T3 (pl) 2016-03-25 2021-11-22 Intra-Cellular Therapies, Inc. Związki organiczne i ich zastosowanie w leczeniu lub zapobieganiu zaburzeniom ośrodkowego układu nerwowego
EP3436083A4 (de) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. Neuartige zusammensetzungen und verfahren
JP2019513143A (ja) 2016-03-28 2019-05-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規塩類および結晶
US11014925B2 (en) 2016-03-28 2021-05-25 Intra-Cellular Therapies, Inc. Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
IL268970B2 (en) 2017-03-24 2023-12-01 Intra Cellular Therapies Inc Oral transmucosal formulations of substituted heterocycle fused gamma carbolines
JP7224333B2 (ja) 2017-07-26 2023-02-17 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP7223742B2 (ja) 2017-07-26 2023-02-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN111107847A (zh) 2017-09-26 2020-05-05 细胞内治疗公司 新的盐和晶体
WO2019178484A1 (en) 2018-03-16 2019-09-19 Intra-Cellular Therapies, Inc. Novel methods
AU2019240226B2 (en) 2018-03-23 2024-11-28 Intra-Cellular Therapies, Inc. Organic compounds
IL321985A (en) 2018-06-06 2025-09-01 Intra Cellular Therapies Inc New salts and crystals
WO2019237037A1 (en) 2018-06-08 2019-12-12 Intra-Cellular Therapies, Inc. Novel methods
CA3106447A1 (en) 2018-06-11 2019-12-19 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines synthesis
EP3843729A4 (de) 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. Neuartige zusammensetzungen und verfahren
CA3108558A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
CN112584837A (zh) 2018-08-31 2021-03-30 细胞内治疗公司 新方法
BR112021011792A2 (pt) 2018-12-17 2021-08-31 Intra-Cellular Therapies, Inc. Composto orgânico
WO2020132605A1 (en) 2018-12-21 2020-06-25 Intra-Cellular Therapies, Inc. Organic compounds
US12195463B2 (en) 2018-12-21 2025-01-14 Intra-Cellular Therapies, Inc. Organic compounds
JP7673040B2 (ja) 2019-07-07 2025-05-08 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規方法
EP4034119A4 (de) 2019-09-25 2023-10-18 Intra-Cellular Therapies, Inc. Neuartige verfahren
EP4072554A4 (de) 2019-12-11 2023-12-20 Intra-Cellular Therapies, Inc. Organische verbindung
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1227447B (de) * 1962-03-30 1966-10-27 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung von Phenylisopropylaminen
HU193662B (en) * 1983-12-20 1987-11-30 Chinoin Gyogyszer Es Vegyeszet Process for producing synergetic pharmaceutical composition of antidepressive aktivity
EP0241809B1 (de) * 1986-04-16 1990-08-08 ASTA Pharma Aktiengesellschaft Synergistische Kombination von Amantadin und Selegilin
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick

Also Published As

Publication number Publication date
DE68919358D1 (de) 1994-12-15
WO1990001928A1 (en) 1990-03-08
CA1329129C (en) 1994-05-03
JPH03500897A (ja) 1991-02-28
HU208484B (en) 1993-11-29
BG60423B2 (bg) 1995-03-31
DE68919358T2 (de) 1995-03-30
HUT51136A (en) 1990-04-28
JPH0818977B2 (ja) 1996-02-28
HK1003978A1 (en) 1998-11-13
US5151419A (en) 1992-09-29
EP0413771A1 (de) 1991-02-27
EP0413771B1 (de) 1994-11-09

Similar Documents

Publication Publication Date Title
ATE113834T1 (de) Zusammensetzung zur behandlung der schizophrenie.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE241365T1 (de) Saccharid-enthaltende zubereitungen zur behandlung von alzheimerschen erkrankung und von weiteren amyloidosen
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
SE9401406D0 (sv) Pharmaceutical products for curing tumourous diseases and process for preparing same
ATE113846T1 (de) Therapeutische zusammensetzungen für die behandlung von myocard-infarkten.
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
ATE201597T1 (de) Verabreichung von riluzol zur behandlung von neuro-aids
UA26403A (uk) Похідhі n-заміщеhого 4-феhіл-4-піперидиhкарбоксаміду та їх фармацевтичhо прийhятhі солі, що проявляють аhестезувальhу та аhальгезувальhу дію, спосіб їх одержаhhя та фармацевтичhа композиція
DE69116380D1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE69634269D1 (de) Verfahren zum modulieren der mikrozirkulation
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
DK0561846T3 (da) 4,5-dihydroxy- og 4,5,8-trihydroxy-9,10-dihydro-9,10-dioxo-2-anthracencarboxylsyre-dicarbonater og -urethaner med terapeutisk virkning
ES2038216T3 (es) Procedimiento para la preparacion de 5-(3-alquil-5-t-butil-4-hidroxi-fenil)-2-amino-6h-1,3,4-tiadazinas y su empleo.
MC1930A1 (fr) Produit antiviral
DE69327314D1 (de) Zusammensetzungen enthaltend Lipoprotein-Associated-Coagulation-Inhibitor (LACI) zur Herstellung eines Medikaments zur Behandlung von akuten oder chronischen Enzündungen
DE58903659D1 (de) Pharmazeutische zubereitung zur behandlung entzuendeter nasenschleimhaeute.
DE69400704D1 (de) N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten
DE69729201D1 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DK0863752T3 (da) Anvendelse af alkylaminderivater såsom terbinafin ved fremstillingen af et lægemiddel til behandling af ledsagende sygdomme af en helicobacter pylori-infektion.
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee